- Home
- NVMI vs TLX Comparison
NVMI vs TLX Comparison
Compare NVMI & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVMI
- TLX
- Stock Information
- Founded
- NVMI 1993
- TLX 2015
- Country
- NVMI Israel
- TLX Australia
- Employees
- NVMI N/A
- TLX N/A
- Industry
- NVMI Electronic Components
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- NVMI Technology
- TLX Health Care
- Exchange
- NVMI Nasdaq
- TLX Nasdaq
- Market Cap
- NVMI 6.3B
- TLX 5.8B
- IPO Year
- NVMI 2000
- TLX N/A
- Fundamental
- Price
- NVMI $268.83
- TLX $19.50
- Analyst Decision
- NVMI Strong Buy
- TLX Strong Buy
- Analyst Count
- NVMI 7
- TLX 1
- Target Price
- NVMI $238.33
- TLX $22.00
- AVG Volume (30 Days)
- NVMI 232.8K
- TLX 18.5K
- Earning Date
- NVMI 02-13-2025
- TLX 01-01-0001
- Dividend Yield
- NVMI N/A
- TLX N/A
- EPS Growth
- NVMI 34.25
- TLX N/A
- EPS
- NVMI 5.75
- TLX 0.09
- Revenue
- NVMI $672,396,000.00
- TLX $484,687,790.00
- Revenue This Year
- NVMI $27.77
- TLX N/A
- Revenue Next Year
- NVMI $6.47
- TLX N/A
- P/E Ratio
- NVMI $47.59
- TLX $217.91
- Revenue Growth
- NVMI 29.83
- TLX 80.92
- 52 Week Low
- NVMI $158.00
- TLX $14.01
- 52 Week High
- NVMI $289.90
- TLX $20.00
- Technical
- Relative Strength Index (RSI)
- NVMI 65.38
- TLX N/A
- Support Level
- NVMI $240.12
- TLX N/A
- Resistance Level
- NVMI $278.62
- TLX N/A
- Average True Range (ATR)
- NVMI 10.03
- TLX 0.00
- MACD
- NVMI 0.94
- TLX 0.00
- Stochastic Oscillator
- NVMI 61.30
- TLX 0.00
About NVMI Nova Ltd.
Nova Ltd is a semiconductor equipment manufacturer. The company provides metrology solutions for process control used in semiconductor manufacturing. The company offers in-line optical and x-ray stand-alone metrology systems, as well as integrated optical metrology systems. The product range consists of Nova 2040, Nova 3090Next, Nova i500 and i500 Plus, Nova T500, Nova T600, Nova V2600, HelioSense 100, Nova Hybrid Metrology solution, NovaMars. The company generates the majority of its revenue from China. Geographically the company has its business spread across the region of Taiwan, Korea, China, the United States, and Europe.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.